CD4 News and Research

RSS

In-depth analysis of SARS-CoV-2 specific T cells in unexposed individuals

A new study aimed to analyze SARS-CoV-2 specific T-cells in unexposed individuals.

2 Dec 2021

SARS-CoV-2 infection risks increase with time in fully vaccinated adults

A recent study describes the association between time elapsed since the second dose of the Pfizer-BioNTech BNT162b2 vaccine and risk of COVID-19.

1 Dec 2021

Scientists identify a new therapeutic target for HIV

Scientists in Montreal and London have identified the key role played by transcription factorRORC2 in HIV infection: the molecule attaches itself to parts of the virus's genome yet doesn't prevent it from replicating.

30 Nov 2021

Efficacy and safety of an RBD-based recombinant protein COVID-19 vaccine

A study developed a protein-based subunit vaccine, PHH-1V, that consisted of a recombinant RBD fusion heterodimer of the alpha) and beta variants of SARS-CoV-2.

26 Nov 2021

Safety and immunogenicity of COVID-19 peptide vaccine

In a study published in Nature, researchers from University Hospital Tübingen have been investigating the results from a Phase I trial for a new vaccine against SARS-CoV-2 variants.

25 Nov 2021

SARS-CoV-2 reinfection and the natural immune response

Researchers review available literature on immunity and SARS-CoV-2 infection to elucidate mechanisms behind SARS-CoV-2 immunity and reinfections.

24 Nov 2021

An assessment of potential epitopes in SARS-CoV-2 structural proteins

Researchers utilized multiple bioinformatics resources to identify potent T- and B-cell epitopes of four SARS-CoV-2 structural proteins.

24 Nov 2021

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

A new study published on the medRxiv* preprint server analyzed the trajectories of anti-SARS-CoV-2 antibodies in patients from the RituxiVac study were compared to healthy volunteers. In addition, they investigated the immunogenicity of a third vaccine dose in previously non-responding patients.

23 Nov 2021

A novel reverse epitope discovery approach to characterize SARS-CoV-2 public CD4+ αβ T cell clonotypes

A new study, published on the bioRxiv* preprint server, has focused on public clonotypes, i.e., clones found in multiple individuals, for the development of a novel reverse epitope discovery technique. This technique holds greater potential for population-wide applications.

23 Nov 2021

Time of starting antiretroviral therapy can influence tumor development In HIV patients

HIV patients have an increased risk of developing skin and mucosal cancers, even though HIV is no longer detectable in their blood due to antiretroviral therapy.

23 Nov 2021

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

Indian researchers determine the magnitude, quality, and persistence of cellular and humoral memory responses after vaccination with BBV152/Covaxin.

23 Nov 2021

CoronaVac vaccine booster strengthens protection against SARS-CoV-2

In a recent study published on the preprint medRxiv* server, an international team of scientists tested CoronaVac as a booster shot and measured its effects on immunity. Their findings showed increases in neutralizing antibodies and T cell response.

21 Nov 2021

Study reveals mechanism by which vitamin D reduces inflammation caused by immune cells

Scientists recently gained insights into how vitamin D functions to reduce inflammation caused by immune cells that might be relevant to the responses during severe COVID-19. In a study jointly published by Purdue University and the National Institutes of Health, scientists do just that.

18 Nov 2021

Study: Covid-19 vaccine-elicited immune cells persist six months after vaccination

A recent study by Johns Hopkins Medicine researchers provides evidence that CD4+ T lymphocytes — immune system cells also known as helper T cells — produced by people who received either of the two available messenger RNA (mRNA) vaccines for COVID-19 persist six months after vaccination at only slightly reduced levels from two weeks after vaccination and are at significantly higher levels than for those who are unvaccinated.

16 Nov 2021

Deficient spike-specific T cell responses and inability to neutralize SARS-CoV-2 variants 12 month post-infection

Researchers conducted a comprehensive, longitudinal, long-term immune study, including functional assays to assess immune fitness against antigenically different VoC. The study is currently available on the preprint server medRxiv* while awaiting peer review.

15 Nov 2021

INTEGRA’s VOYAGER helps HIV researchers get more results in significantly less time

INTEGRA’s VOYAGER adjustable tip spacing pipette is supporting crucial experimental work in longitudinal HIV studies.

From INTEGRA Biosciences 12 Nov 2021

Immunity following COVID-19 vaccination and natural infection in India

The researchers evaluated immune response markers in a cross-section of people from the Indian state of West Bengal, including those vaccinated with either Covishield or Covaxin, the unvaccinated cohort, and the naturally infected.

11 Nov 2021

Evidence that mild and even asymptomatic SARS-CoV-2 infection can lead to sustained immune activation

A paper published in the open-access journal Viruses, reports on a study investigating long-term changes to soluble inflammatory factors and cellular immune phenotype and function in 22 survivors of mild SARS-CoV-2 infection. The observations were then compared to 11 individuals who had recovered from other mild respiratory infections.

10 Nov 2021

Chronological changes in SARS-CoV-2 immune responses after BNT162b2 vaccine

A new study focused on the chronological changes in humoral and cell-mediated immune responses, during and after the BNT162b2 vaccine administration, among hospital workers of a national medical institution in Japan.

10 Nov 2021

The role of T follicular helper cells in the humoral immune response to SARS-CoV-2

The current analysis indicates that cTfh cells react to the spike antigen following vaccination are associated with anti-S protein neutralizing antibodies.

9 Nov 2021

CD4 News and Research

In-depth analysis of SARS-CoV-2 specific T cells in unexposed individuals

SARS-CoV-2 infection risks increase with time in fully vaccinated adults

Scientists identify a new therapeutic target for HIV

Efficacy and safety of an RBD-based recombinant protein COVID-19 vaccine

Safety and immunogenicity of COVID-19 peptide vaccine

SARS-CoV-2 reinfection and the natural immune response

An assessment of potential epitopes in SARS-CoV-2 structural proteins

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

A novel reverse epitope discovery approach to characterize SARS-CoV-2 public CD4+ αβ T cell clonotypes

Time of starting antiretroviral therapy can influence tumor development In HIV patients

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

CoronaVac vaccine booster strengthens protection against SARS-CoV-2

Study reveals mechanism by which vitamin D reduces inflammation caused by immune cells

Study: Covid-19 vaccine-elicited immune cells persist six months after vaccination

Deficient spike-specific T cell responses and inability to neutralize SARS-CoV-2 variants 12 month post-infection

INTEGRA’s VOYAGER helps HIV researchers get more results in significantly less time

Immunity following COVID-19 vaccination and natural infection in India

Evidence that mild and even asymptomatic SARS-CoV-2 infection can lead to sustained immune activation

Chronological changes in SARS-CoV-2 immune responses after BNT162b2 vaccine

The role of T follicular helper cells in the humoral immune response to SARS-CoV-2

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News